Pathophysiology Of Pyoderma Gangrenosum: The Role Of Neutrophils And Inflammation.

Pyoderma gangrenosum (PG) is a rare, painful, and quick progressive skin condition. It is commonly associated with other systemic diseases, such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), and hematologic disorders. The development of necrotic, ulcerative lesions characterises the condition. Despite its well-established clinical manifestations, the specific pathophysiology of PG remains unknown. However, recent research has highlighted the central role of neutrophils and the inflammatory response in the development and progression of PG. In this article, we will explore our current understanding of the pathophysiology of PG, with a focus on the role of neutrophils and inflammation in the disease process.

Overview of pyoderma gangrenosum

Pyoderma gangrenosum belongs to a group of neutrophilic dermatoses, a category of diseases characterised by the infiltration of neutrophils into various tissues, especially the skin. The hallmark of PG is the rapid onset of painful, purulent ulcers, often with irregular borders and a violaceous hue. These ulcers may enlarge rapidly, leading to deep tissue necrosis and scarring, which can result in permanent disfigurement. While PG is more frequently observed in patients with underlying conditions such as Crohn's disease, ulcerative colitis, RA, and hematologic malignancies, it can also occur in healthy individuals with no obviouspredisposing conditions.

Research evidence suggests that neutrophil dysfunction, combined with an exaggerated inflammatory response, plays a central role in the disease. Furthermore, an immune-mediated process, often involving cytokines and chemokines, drives the inflammation and tissue destruction seen in PG.

The role of neutrophils in pyoderma gangrenosum

Neutrophils are essential components of an individual's innate immune response, tasked with defending the body against infection and injury. They are the most abundant type of white blood cell in the human body and are among the first immune cells to migrate to sites of infection or inflammation. At the site of injury, neutrophils help to neutralise pathogens through phagocytosis, the release of antimicrobial peptides, and the production of reactive oxygen species (ROS).

In the context of PG, neutrophils appear to be both hyperactive and dysfunctional. Under normal circumstances, neutrophils undergo a tightly regulated process of activation and recruitment, ensuring that they respond appropriately to infection or injury. In PG, however, the activation and recruitment of neutrophils occur inappropriately, even in the absence of an infectious agent. This dysregulation leads to the accumulation of neutrophils in the skin, where they become a source of tissue damage.

Histopathological examination of PG lesions consistently reveals a large number of neutrophils in the dermis, forming what are known as "neutrophilic abscesses" in the upper dermis and epidermis. The neutrophilic infiltrate in PG is often associated with the presence of tissue necrosis, further implicating neutrophils in the pathological process. Neutrophils can release a variety of inflammatory mediators, such as cytokines and proteolytic enzymes, which promote further tissue injury and ulceration.

Neutrophilic hyperactivation in pyoderma gangrenosum

Recent studies suggest that neutrophils in PG may become hyperactivated, meaning they respond more aggressively to stimuli than they would under normal conditions. Various factors, including the release of pro-inflammatory cytokines, immune complexes, and autoantibodies could drive this hyperactivation. Once activated, neutrophils release several pro-inflammatory cytokines, including tumour necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-8 (IL-8), which in turn recruit additional neutrophils to the site of inflammation.

One of the most important mediators of neutrophil activation in PG is the granulocyte-macrophage colony-stimulating factor (GM-CSF). This cytokine plays a crucial role in neutrophil maturation, survival, and activation. Elevated levels of GM-CSF have been observed in the serum of patients with PG, suggesting that it may play a role in the pathogenesis of the disease. Along with GM-CSF, TNF-α is another cytokine implicated in the pathogenesis of PG. TNF-α has been shown to induce the production of other pro-inflammatory cytokines, amplifying the inflammatory response and leading to more extensive tissue damage.

The release of reactive oxygen species (ROS) by neutrophils plays a critical role in the development of tissue damage in PG. ROS are highly reactive molecules that can cause cellular injury by damaging lipids, proteins, and DNA. In PG lesions, ROS are thought to contribute to the necrosis of surrounding tissue, accelerating the ulcerative process.

The role of inflammation in pyoderma gangrenosum

Inflammation is a central feature of PG and is responsible for most of the tissue destruction seen in the disease. Within PG, inflammation is not only a consequence of neutrophil infiltration but also a driving force behind the progression of the disease. The inflammatory process in PG is mediated by immune system dysregulation, which involves the activation of neutrophils and the production of cytokines.

The primary inflammatory mediators in PG are cytokines and chemokines- small proteins that regulate the recruitment and activation of immune cells. In PG, these mediators are produced in excess, leading to an exaggerated inflammatory response. Some of the most important cytokines involved in PG include interleukin-1 (IL-1), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α), and interleukin-8 (IL-8). These cytokines work in concert to recruit and activate neutrophils, resulting in the formation of neutrophilic abscesses in the skin.

In addition to cytokines, chemokines play a key role in recruiting neutrophils to the site of inflammation. Chemokines such as CXCL1 and CXCL8 are produced in response to tissue injury and are responsible for guiding neutrophils to the affected area. Once neutrophils reach the site of inflammation, they release various inflammatory mediators that can further exacerbate tissue damage, creating a vicious cycle of inflammation and tissue destruction.

One of the most essential features of PG is the formation of ulcers, which is thought to be driven by the combined effect of neutrophil activation and the release of inflammatory mediators. The intense inflammatory response destroys the dermal and epidermal layers of the skin, creating an ulcer with raised, violaceous borders and undermined edges. As the ulcer enlarges, surrounding tissues begin to necrotise. Genetic and Environmental Factors in Pyoderma Gangrenosum

Although PG's exact cause remains unknown, genetic and environmental factors appear to contribute to the disease. Several genetic mutations associated with immune dysregulation have been identified in patients with PG, particularly in those with underlying systemic diseases such as IBD and RA. For example, mutations in the NOD2 gene, which is involved in the immune response to bacterial pathogens, have been linked to PG in patients with Crohn's disease. Similarly, genetic mutations affecting the IL-23/Th17 axis have been implicated in the pathogenesis of PG, particularly in patients with inflammatory bowel disease (IBD).

Environmental factors, such as trauma or surgery, can also trigger the onset of PG. This phenomenon, known as pathergy, is a well-established feature of PG. Pathergy refers to the development of new lesions following minor trauma or injury, and it is thought to result from an exaggerated immune response to tissue damage. In PG, trauma may lead to the release of damage-associated molecular patterns (DAMPs), which can trigger an inflammatory response and recruit neutrophils to the site of injury. This process can initiate or exacerbate the development of PG lesions, resulting in the characteristic ulceration and tissue necrosis.

Current treatment approaches

The management of PG remains challenging due to the lack of a clear understanding of its underlying mechanisms. Treatment typically involves controlling inflammation and managing the underlying conditions that may be contributing to the disease. First-line treatments often include systemic corticosteroids, which help to reduce inflammation, as well as immunosuppressive agents such as azathioprine or methotrexate. For patients with severe or refractory PG, biologic therapies targeting specific cytokines, such as TNF-α inhibitors (e.g., infliximab), have shown promise in controlling disease activity. Therapy aims to suppress the hyperactive immune response, reduce inflammation, and promote healing of the ulcers.

Summary

The pathophysiology of pyoderma gangrenosum is complex and not fully understood, but research has increasingly highlighted the central role of neutrophils and inflammation in its development. Neutrophilic dysfunction and hyperactivation lead to the release of pro-inflammatory mediators, contributing to PG's tissue damage and ulceration characteristics. Additionally, an interplay of genetic and environmental factors likely contributes to the onset and progression of the disease. Understanding the molecular and cellular mechanisms underlying PG will be essential for developing more effective therapies and improving outcomes for affected patients.

Bibliography

Alavi A, French LE, Davis MDP, Brassard A, Kirsner RS. Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. American Journal of Clinical Dermatology. 2017 Feb 21;18(3):355–72. Available from: https://pubmed.ncbi.nlm.nih.gov/28224502/

Choe, S., Bourgeois, J., Nidamanuri, S., & Rubenzik, R. (2024). Pyoderma Gangrenosum in an Ulcerative Colitis Patient on Vedolizumab. Cureus. https://doi.org/10.7759/cureus.69219

Skopis M, Bag-Ozbek A. Pyoderma Gangrenosum: A Review of Updates in Diagnosis, Pathophysiology and Management. 2021 Jul 19;4(3):367–75. Available from: https://www.mdpi.com/2571-8800/4/3/28